Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.56 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780585 | 1.00 | ADORA3 (0.66) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL4425850 | 0.90 | ADORA3 (0.56) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL7197169 | 0.87 | TYMP (0.68) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL15245129 | 0.87 | ADORA3 (0.65) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL41361 | 0.87 | ADORA1 (0.74) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL15788449 | 0.87 | ADORA1 (0.74) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL15338536 | 0.87 | ADORA1 (0.74) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL384075 | 0.87 | ADORA1 (0.74) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL15926827 | 0.87 | ADORA1 (0.74) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 | |
| SCHEMBL6560740 | 0.87 | TYMP (0.68) | ADORA3ADORA1P2RY1SMN1; SMN2P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119614577-A | Anti-CD 3 nucleic acid aptamer for cell targeting and labeling | 艾夏卡法国有限公司 | 2025-03-14 | — | — | CN | claimed |
| WO-2024077351-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2024-04-18 | — | — | WO | claimed |
| CN-116916936-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2023-10-20 | — | — | CN | claimed |
| US-20220251562-A1 | Anti-CD3 Aptamers for Use in Cell Targeting and Labeling | IXAKA FRANCE (FR) | 2022-08-11 | — | — | US | claimed |
| CN-114630907-A | anti-CD 3 aptamers for cell targeting and labeling | 艾夏卡法国有限公司 | 2022-06-14 | — | — | CN | claimed |
| EP-4004209-A2 | ANTI-CD3 APTAMERS FOR USE IN CELL TARGETING AND LABELING | IXAKA FRANCE (FR) | 2022-06-01 | — | — | EP | claimed |
| WO-2021019301-A2 | ANTI-CD3 APTAMERS FOR USE IN CELL TARGETING AND LABELING | ARATINGA.BIO ACI (FR) | 2021-02-04 | — | — | WO | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| CN-106232834-A | Sample preparation methods | 牛津纳米孔技术公司 | 2016-12-14 | — | — | CN | claimed |
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | claimed |
| EP-2512491-A1 | HBV ANTISENSE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | claimed |
| WO-2011047312-A1 | HBV ANTISENSE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | WO | claimed |
| US-20100254901-A1 | Compositions comprising nucleic acid aptamers | SMITH CASSANDRA L | 2010-10-07 | — | — | US | claimed |
| CN-101346474-A | Selectable nucleotides for improved targeted nucleotide exchange | KEYGENE NV (NL) | 2009-01-14 | — | — | CN | claimed |
| US-20070082863-A1 | Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds | IRX THERAPEUTICS, INC. | 2007-04-12 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-5075225-A | PROCESS FOR THE ENZYMATIC SYNTHESIS OF NUCLEOSIDES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1991-12-24 | — | — | US | claimed |
| EP-0391592-A1 | Process for the enzymatic synthesis of nucleosides | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1990-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082863-A1 | Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds | INMT, STING1, ITPA | ADORA3 92/4885ADORA1 76/4885P2RY1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.